In rats with short bowel syndrome, BPC-157 caused immediate weight gain and improved intestinal features following oral and intraperitoneal administration [17]
In animal toxicology studies, no significant adverse effects have been observed even at doses far exceeding typical therapeutic ranges
Many treatment modalities have been developed to restore the immune tolerance and immmunoregulatory balance in autoimmune rheumatic diseases, including the use of peptide-based therapeutics or the use of nanoparticles-based nanotechnology
Disclosures: Binu John: Exact Sciences: Grant/Research Support, Genentech: Grant/Research Support, Glycotest, Inc: Grant/Research Support, Gilead: Grant/Research Support, Exelixis: Consultant, Takeda: Grant/Research Support, GlaxoSmithKline: Consultant, Astra Zeneca: Consultant, Dustin Bastaich: Nothing to Disclose, Catherine Mezzacappa: Nothing to Disclose, Raphaella Ferreira: Nothing to Disclose, Austen Hentschel: Nothing to Disclose, Andres Samos: Nothing to Disclose, Nadim Mahmud: Nothing to Disclose, Tamar Taddei: Nothing to Disclose, David Kaplan: AstraZeneca Inc: Grant/Research Support, Roche Genentech: Independent Contractor, Exact Sciences: Grant/Research Support, Glycotest: Grant/Research Support, Sirtex: Advisor, Exelixis: Advisor, AstraZeneca: Advisor, Marina Serper: Transplant Genomics: Grant/Research Support, Grifols: Grant/Research Support, Eurofins: Grant/Research Support, Bassam Dahman: Nothing to Disclose 2073 HYDROPHOBIC SECONDARY BILE ACIDS INDUCE PRIMARY SCLEROSING CHOLANGITIS THROUGH THE LIVER-LARGE INTESTINE AXIS IN A CYP2C70 -/- / CYP2A12 -/- MOUSE WITH HUMAN-TYPE BILE ACID COMPOSITION -/- -/- Teruo Miyazaki 1 Hajime Ueda 1 Tadashi Ikegami 1 Akira Honda 1 , 1 Tokyo Medical University Ibaraki Medical Center Background: Primary sclerosing cholangitis (PSC) is characterized by fibrosis around the large bile duct (onion-skin lesions) and frequently complicates inflammatory bowel diseases (IBD)
